Key Details
The amendment fundamentally changes how syrup-based medicines are distributed and dispensed, particularly in rural areas that previously benefited from Schedule K exemptions.
Area | Key Change |
|---|---|
Legal Amendment | “Syrup” deleted from Schedule K (Serial No. 13, Entry 7) of the Drugs Rules, 1945 |
OTC Status | Over-the-counter sale of syrup formulations discontinued |
Prescription Requirement | Syrup-based medicines now require a valid prescription from a registered medical practitioner |
Rural Distribution | Exemptions available to villages below 1,000 population removed for syrup formulations |
Retail Channel | Dispensing restricted to licensed pharmacies complying with the Drugs and Cosmetics Act, 1940 |
Regulatory Process | Amendment finalized after public consultation and DTAB review |
Pediatric Guidance | NFI 2026 advises against use in children below two years and discourages routine use below five years |
Summary
Schedule K Amendment Removes Syrup Exemption Nationwide
The Ministry of Health and Family Welfare (MoHFW) has notified the Drugs (Fifth Amendment) Rules, 2026, deleting the word “Syrup” from Schedule K of the Drugs Rules, 1945. The change removes a long-standing exemption that permitted the sale of certain syrup formulations through non-pharmacy retail outlets, including in villages with populations below 1,000 persons. The amendment brings oral liquid medicines under a stricter regulatory framework across the country.
Syrups Shift to Prescription-Only and Licensed Pharmacy Channels
Following the amendment, syrup-based medicines can now be dispensed only through licensed pharmacies and against a valid medical prescription. While tablets, lozenges and other solid formulations continue under existing Schedule K provisions, oral liquid formulations will no longer be available through exempt retail channels. The measure strengthens product traceability and supply-chain accountability.
Regulatory Response to Contamination and Child Safety Concerns
The reform follows heightened scrutiny of cough syrup safety after incidents involving diethylene glycol (DEG) and ethylene glycol (EG) contamination that resulted in severe acute kidney injury and child deaths. By restricting syrup distribution to regulated channels, the government aims to improve surveillance, facilitate batch recalls, and reduce the risk of unsafe products reaching consumers.
DTAB Review and National Pediatric Guidance
The amendment was finalized after public consultation and review by the Drugs Technical Advisory Board (DTAB). It also aligns with the National Formulary of India (NFI) 2026, which advises that cough and cold medicines should not be prescribed to children below two years of age and are generally discouraged for children below five unless clinically justified and supervised by a healthcare professional.
A Significant Shift in Rural Pharmaceutical Regulation
The removal of the syrup exemption marks one of the most consequential changes to Schedule K in recent years. By ending population-based retail exemptions and requiring licensed dispensing channels, the government is seeking to strengthen medicine safety standards, particularly in rural and underserved areas where regulatory oversight has historically been weaker.
What is Schedule K?
Schedule K is a component of the Drugs Rules, 1945 that provides exemptions from certain licensing and regulatory requirements for specified medicines and products. Historically, these exemptions were designed to improve access to basic medicines, particularly in remote and underserved areas where licensed pharmacies were limited.
Changes to Schedule K therefore directly influence how medicines can be sold, distributed, and monitored across the country.
Policy Relevance
The amendment strengthens pharmaceutical traceability and patient safety by moving syrup-based medicines from exemption-based distribution channels into a prescription-led, licensed pharmacy framework.
Reduces the risk of contaminated liquid medicines reaching consumers by strengthening oversight of manufacturing and distribution channels.
Improves traceability and recall capacity by ensuring syrup formulations move through regulated pharmaceutical networks.
Closes regulatory gaps in rural medicine distribution by applying more uniform dispensing standards across villages and urban areas.
Supports safer pediatric medicine use through alignment with updated National Formulary guidance.
Strengthens public confidence in medicine quality and regulatory oversight following high-profile contamination incidents.
Provides regulators with better visibility across pharmaceutical supply chains, improving enforcement and surveillance capabilities.
Relevant Question for Stakeholders: How can CDSCO and state drug regulators build a nationwide digital traceability system for syrup-based medicines that links manufacturers, distributors, pharmacies, and prescriptions to enable rapid identification and recall of unsafe products?
Follow the Full News Here: Union Ministry of Health and Family Welfare Amends Drugs Rules, 1945